© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Sonnet BioTherapeutics Holdings, Inc. (SONN) stock surged +2.37%, trading at $1.73 on NASDAQ, up from the previous close of $1.69. The stock opened at $1.69, fluctuating between $1.67 and $1.75 in the recent session.
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Employees | 12 |
Beta | 1.04 |
Sales or Revenue | $18.63K |
5Y Sales Change% | -1% |
Fiscal Year Ends | September |
Sector | Healthcare |
Industry | Biotechnology |
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) stock price is $1.73 in the last trading session. During the trading session, SONN stock reached the peak price of $1.75 while $1.67 was the lowest point it dropped to. The percentage change in SONN stock occurred in the recent session was 2.37% while the dollar amount for the price change in SONN stock was $0.04.
The NASDAQ listed SONN is part of Biotechnology industry that operates in the broader Healthcare sector. Sonnet BioTherapeutics Holdings, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Jay Cross
Chief Financial Officer
Mr. Donald J. Griffith CPA, CPA
Controller & Director
Dr. Pankaj Mohan Ph.D.
Founder, Chairman, Chief Executive Officer & Pres
Ms. Susan Dexter
Chief Technical Officer
Mr. Manuel Dafonseca
Head of Clinical Operations
Dr. Richard T. Kenney FACP, M.D.
Chief Medical Officer
Dr. John K. Cini Ph.D.
Chief Scientific Officer & Co-Founder
Mr. Donald J. Griffith C.P.A., CPA
Controller & Director
SONN's closing price is 22.7% higher than its 52-week low of $1.41 where as its distance from 52-week high of $18.72 is -90.76%.
Number of SONN employees currently stands at 12.
Official Website of SONN is: https://www.sonnetbio.com
SONN could be contacted at phone 609 375 2227 and can also be accessed through its website. SONN operates from 100 Overlook Center, Princeton, NJ 08540, United States.
SONN stock volume for the day was 48.2K shares. The average number of SONN shares traded daily for last 3 months was 1.49M.
The market value of SONN currently stands at $5.20M with its latest stock price at $1.73 and 3.01M of its shares outstanding.